Novan, Inc. (NOVN), today announced the election of Steven D. Skolsky to its Board of Directors. Mr. Skolsky is a well-established senior executive with over 35 years of experience in healthcare and the life sciences in both private and public sectors.
Syneos Health Communications the portfolio of Syneos Health® agencies designed to deliver insights-driven integrated communications spanning advertising, public relations, patient advocacy, medical communications, managed markets, omnichannel, digital, naming and branding has hired five senior specialists to deepen its leading market access and external affairs offerings.
Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years Celsion Corporation (CLSN), a clinical stage development company focused on DNA based immunotherapy and next generation vaccines, today announced it has received approval from the New Jersey Economic Development Authoritys Technology Business Tax Certificate Transfer program to sell $2 million of its...
Expertise in Clinical Development, Regulatory Affairs and Manufacturing Represented Connectyx Technologies Holdings Group, Inc. (CTYX), Connectyx (CTYX) announced today the addition of three industry veterans to the companys management team. Chairman Michaels noted, When I began the journey as interim chief executive officer, I knew that as the company progressed, more world-class talent would be needed.
BOSTON and DURHAM, N.C. and FT. The collaboration with NeoGenomics (NEO) will enhance Parexels use of real-world data across various applications, including identifying and estimating prevalence of genomic mutations within respective populations, genomic patterning to stratify patients according to novel biomarkers, and use of de-identified patient data to precisely target patient populations.
Nozomi Networks Inc., the leader in OT and IoT security, today announced record 2020 growth and tremendous momentum moving into 2021. In 2020 Nozomi Networks market share neared 50% among the worlds top pharmaceutical, oil and gas, electric utility and mining operations.
Precision BioSciences, Inc. (DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced the closing of its in vivo gene editing research collaboration and exclusive license agreement with Eli Lilly and Company following clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
Seqens CDMO North America, a pharmaceutical manufacturer of new chemical entities, active pharmaceutical ingredients, and other specialty chemical products, issued its annual list of trends that will affect the emerging pharmaceutical and generic drug sectors, as well as Contract Development and Manufacturing Organizations, in 2021.
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.